The evolution of ideas about the treatment of Alzheimer’s disease: from the past to the present day

Cognitive disorders are one of the most important manifestations of various cerebral pathologies. Among all the nosological forms that occur with the formation of dementia, Alzheimer’s disease is the most common. At various stages of historical development, scientists conducted numerous studies aimed at establishing effective means of its therapy. In ancient times, the emphasis was on the use of such means as baths, diets, wine, massage, mental training. In addition, various rites and rituals were practiced. A large role was given to the use of decoctions, tinctures based on medicinal plants, often with the addition of minerals and animal products. In the XIX century, physical care, being in a family environment, attempts to involve in everyday activities, restrictive measures became widespread. In the process of the development of sciences at the beginning of the XX century, pharmacological preparations began to be used. Initially, these were sedatives and diuretics based on bromine and iodine. Then vasodilating and other “vascular” means came into practice. As data on the pathogenesis of the disease accumulated, drugs that affect cholinergic transmission and other mediator systems were developed. There have also been attempts to use drugs with neurotrophic, antioxidant, and anti-inflammatory properties. The most modern direction of therapy, taking into account the main pathobiochemical changes formed in the brain in Alzheimer’s disease, is an antiamyloid strategy aimed at modifying the course of the disease.

1. Fiest K.M., Roberts J.I., Maxwell C.J., Hogan D.B., Smith E.E., Frolkis A. et al. The Prevalence and Incidence of Dementia Due to Alzheimer’s Disease: a Systematic Review and Meta-Analysis. Can. J. Neurol. Sci. 2016;1:51–82. https://doi.org/10.1017/cjn.2016.36

2. Alzheimer’s Association. 2019. Alzheimer’s Disease Facts and Figures. Alzheimer’s Dementia. 2019;15(3):321–387. https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf.

3. Grmek M.D. Gerontology. The doctrine of old age and longevity. Moskva: Nauka; 1964:132 p. (In Russian).

4. Uzhegov G.N. Recipes of ancient medicine. Smolensk: Rusich; 1997:464 p. (In Russian).

5. Butkovskij P. Mental pain, presented in accordance with the beginnings of the current science of psychiatry. Sankt Peterburg: tipografiya I. Glazunova; 1834:329 p. (In Russian).

6. Bleuler E. Handbook of Psychiatry. Berlin: Izd. tovarishchestva «Vrach», 1920, Moskva: Izd. «Nezavisimaya Psihiatricheskaya associaciya»; 1993:542 p. (In Russian).

7. Gilyarovskij VA. Psychiatry. Мoskva: Medgiz; 1954:520 p. (In Russian).

8. Kral V.A., Cahn C., Deutsch M., Mueller H., Solyom L. Procaine (novocain) treatment of patients with senile and arteriosclerotic brain disease. Can. Med. Assoc. J. 1962;87:1109–1113. PMC1849821

9. Kerbikov O.V., Korkina M.V., Nadzharov R.A., Snezhnevskij A.V. Psychiatry. Мoskva: Medicina; 1968:448 p. (In Russian).

10. Judge T.G. Drugs and dementia. Br. J. Clin. Pharmacol. 1976;3(1):81–82. PMC2958728

11. Winblad B., Fioravanti M., Dolezal T., Logina I., Milanov I.G., Popescu D.C., Solomon A. Therapeutic use of nicergoline. Clin. Drug. Investig. 2008;28(9):533–52. https://doi.org/10.2165/00044011-200828090-00001

12. Szatmari S.Z., Whitehouse P.J. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2003;(1):CD003119. https://doi.org/10.1002/14651858.CD003119

13. Lopez-Arrieta J.M., Birks J. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst. Rev. 2002;3:CD000147. https://doi.org/10.1002/14651858.Cd000147

14. Gavrilova S.I. Pharmacotherapy of Alzheimer’s disease. Мoskva: Pul’s; 2007:360 p. (In Russian).

15. Yahno N.N., Zaharov V.V., Lokshina F.B., Gavrilova S.I., Fedorova Ya.B., Gustov A.V. et al. Tanakan (EGb 761) in the treatment of moderate cognitive impairment (multicenter study). Journal of Neurology and Psychiatry. 2006;12:48–53. (In Russian).

16. Emelin A.Yu., Lobzin V.Yu. The possibilities of drug therapy for vascular cognitive disorders: a critical view and possible compromises. Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):131–136. (In Russian). https://doi.org/10.14412/2074-2711-2020-4-131-136

17. Little A., Levy R., Chuaqui-Kidd P., Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry. 1985;48(8):736–742. https://doi.org/10.1136/jnnp.48.8.736

18. Peters B.H., Levin H.S. Effects of physostigmine and lecithin on memory in Alzheimer’s disease. Ann. Neurol. 1979;6:219–221. https://doi.org/10.1002/ana.410060307

19. Bukatina E.E., Grigor’eva I.V., Sokol’chik E.I. The effectiveness of amiridine in senile dementia of the Alzheimer’s type. Journal of Neurology and Psychiatry. 1991;91(9):53–58 (In Russian).

20. Holford N.H., Peace K.E. Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc. Natl. Acad. Sci USA. 1992;89(23):11471–11475.

21. Birks J.S., Harvey R.J. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst. Rev. 2018;6:CD001190. https://doi.org/10.1002/14651858.CD001190.pub3

22. Konorev M.R., Krapivko I.I., Sobolenko T.M., Akulyonok A.V., Dorozhkina O.P., Solkin A.A., et al. Mikhail Davydovich Mashkovsky: contribution to modern medicine (to the 110th anniversary of the scientist’s birth). Vestnik farmacii. 2018;79(1):95–102. (In Russian).

23. Olin J., Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst. Rev. 2002;3:CD001747.

24. Baakman A.C, ‘t Hart E., Kay D.G., Stevens J., Klaassen E.S., Maelicke A., Groeneveld G.J. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Alzheimers Dement (NY). 2016;2(1):13–22. https://doi.org/10.1016/j.trci.2015.12.003

25. Cummings J., Froelich L., Black S.E., Bakchine S., Bellelli G., Molinuevo J.L. et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2012;33(5):341–53. https://doi.org/10.1159/000340056

26. Dou K.X., Tan M.S., Tan C.C., Cao X.P., Hou X.H., Guo Q.H. et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer’s disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res. Ther. 2018;10(1):126. https://doi.org/10.1186/s13195-018-0457-9

27. Parfenov V.A. Vascular cognitive disorders. Application of Choline Alfoscerate. Nervous diseases. 2013;2:3–8. (In Russian).

28. Poirier J., Miron J., Picard C. Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents. In book: Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. 5th edition, published by Elsevier, 2015:51–62. https://doi.org/10.1016/B978-0-12-410529-4.00004-8

29. Wienrich M., Meier D., Ensinger H.A., Gaida W., Raschig A., Walland A., Hammer R. Pharmacodynamic profile of the M1 agonist talsaclidine in animals and man. Life Sci. 2001;68(22–23):2593–2600. https://doi.org/10.1016/s0024-3205(01)01057-8

30. Nishizaki T., Matsuoka T., Nomura T., Kondoh T., Watabe S., Shiotani T., Yoshii M. Presynaptic nicotinic acetylcholine receptors as a functional target of nefiracetam in inducing a long-lasting facilitation of hippocampal neurotransmission. Alzheimer Dis. Assoc. Disord. 2000;1:82–94. https://doi.org/10.1097/00002093-200000001-00013

31. Ren K., King M.A., Liu J., Siemann J., Altman M., Meyers C. et al. The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience. 2007;148(1):230–237. https://doi.org/10.1016/j.neuroscience.2007.05.013

32. Miyazaki S., Onodera K., Imaizumi M., Timmerman H. Effects of clobenpropit (VUF-9153), a histamine H3-receptor antagonist, on learning and memory, and on cholinergic and monoaminergic systems in mice. Life Sci. 1997;61:355–361. https://doi.org/10.1016/s0024-3205(97)00406-2

33. Rockwood K., Beattie B.L. A randomized, controlled trial of linopirdine in the treatment of Alzheimer’s disease. Can. J. Neurol. Sci. 1997;24(2):140–145. https://doi.org/10.1017/s031716710002148x

34. Folch J., Busquets O., Ettcheto M., Sánchez-López E., CastroTorres R.D., Verdaguer E. et al. Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. J. Alzheimers Dis. 2018;62(3):1223–1240. https://doi.org/10.3233/JAD-170672

35. Lynch G., Granger R., Ambros-Ingerson J., Davis C.M., Kessler M., Schehr R. Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp. Neurol. 1997;145(1):89–92. https://doi.org/10.1006/exnr.1997.6447

36. Bachurin S., Bukatina E., Lermontova N., Tkachenko S., Afanasiev A., Grigoriev V. et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann. NY Acad. Sci. 2001;939:425–435. https://doi.org/10.1111/j.1749-6632.2001.tb03654.x

37. Dysken M., Kuskowski M., Love S. Ondansetron in the treatment of cognitive decline in Alzheimer dementia. Am. J. Geriatr. Psychiatry. 2002;10(2):212–215.

38. Emelin A.Yu., Lobzin V.Yu., Vorob’ev S.V. Cognitive disorders: a guide for doctors. Мoskva, 2019:416 p. (In Russian).

39. Grundman M., Capparelli E., Kim H.T., Morris J.C., Farlow M., Rubin E.H. et al. Alzheimer’s Disease Cooperative Study. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer’s disease patients. Life Sci. 2003;73(5):539–53. https://doi.org/10.1016/s0024-3205(03)00320-5